✦ LIBER ✦

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC)

✍ Scribed by Goto, Koichi; Nishio, Makoto; Yamamoto, Noboru; Chikamori, Kenichi; Hida, Toyoaki; Maemondo, Makoto; Katakami, Nobuyuki; Kozuki, Toshiyuki; Yoshioka, Hiroshige; Seto, Takashi; Fukuyama, Tamaki; Tamura, Tomohide

Book ID: 122240443
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 948 KB
Volume: 82
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2013.07.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erlotinib as first-line treatment of Eur

Erlotinib as first-line treatment of European non-small-cell lung cancer (NSCLC) patients (pts.) with epidermal growth factor receptor (EGFR) activating mutations (mut+)

✍ Petruzelka, Lubos 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 43 KB

Phase I/II trial of vorinostat (SAHA) an

Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression

✍ Reguart, Noemi; Rosell, Rafael; Cardenal, Felipe; Cardona, Andres F.; Isla, Dolo 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 645 KB

Erlotinib versus chemotherapy as first-l

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

✍ Caicun Zhou; Yi-Long Wu; Gongyan Chen; Jifeng Feng; Xiao-Qing Liu; Changli Wang; 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 265 KB

Erlotinib alone or with bevacizumab as f

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

✍ Seto, Takashi; Kato, Terufumi; Nishio, Makoto; Goto, Koichi; Atagi, Shinji; Hoso 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 398 KB

Phase II trial of erlotinib in patients

Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics

✍ Motoshima, Kohei; Nakamura, Yoichi; Sano, Kazumi; Ikegami, Yoji; Ikeda, Takaya; 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 227 KB

Erlotinib versus standard chemotherapy a

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

✍ Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massut 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 246 KB